​

Adial Pharmaceuticals Stock (NASDAQ:ADIL)

OwnershipFinancialsChart
Adial Pharmaceuticals by TradingView

Previous Close

$0.36

52W Range

$0.22 - $1.30

50D Avg

$0.37

200D Avg

$0.57

Market Cap

$7.96M

Avg Vol (3M)

$1.15M

Beta

1.36

Div Yield

-

ADIL Company Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

5

IPO Date

Jul 27, 2018

Website

ADIL Performance

ADIL Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-8.28M$-6.89M$-13.32M
Net Income$-13.20M$-7.00M$-12.73M
EBITDA$-8.28M$-7.00M$-13.32M
Basic EPS$-0.71$-5.44$-11.98
Diluted EPS$-0.71$-5.44$-11.98

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
HCWBHCW Biologics Inc.
SNGXSoligenix, Inc.
NRSNNeuroSense Therapeutics Ltd.
ACXPAcurx Pharmaceuticals, Inc.
BCLIBrainstorm Cell Therapeutics Inc.
APREAprea Therapeutics, Inc.
VYNEVYNE Therapeutics Inc.
BCDABioCardia, Inc.